Harrow Inc
HROW46.650USD
-0.540-1.14%
Market hours （ET）Quotes delayed by 15 min
1.73BMarket Cap
LossP/E TTM
More Details of Harrow Inc Company
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Harrow Inc Info
Ticker SymbolHROW
Company nameHarrow Inc
IPO dateFeb 08, 2013
CEOMullery (Frank)
Number of employees382
Security typeOrdinary Share
Fiscal year-endFeb 08
Address1A Burton Hills Blvd
CityNASHVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code37215
Phone16157334731
Websitehttps://www.harrow.com/
Ticker SymbolHROW
IPO dateFeb 08, 2013
CEOMullery (Frank)
Company Executives of Harrow Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.99M
+100006.00%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
811.18K
+33335.00%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Randall E. Pollard, CPA
Mr. Randall E. Pollard, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Frank Mullery
Mr. Frank Mullery
Chief Executive Officer of ImprimisRx
Chief Executive Officer of ImprimisRx
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.99M
+100006.00%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
811.18K
+33335.00%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Product Sales Net
71.50M
0.00%
Transfer of acquired product sales/profit
141.00K
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product Sales Net
71.50M
0.00%
Transfer of acquired product sales/profit
141.00K
0.00%
Shareholding Stats
Updated: Tue, Nov 25
Updated: Tue, Nov 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Opaleye Management Inc.
10.49%
Baum (Mark L)
8.06%
BlackRock Institutional Trust Company, N.A.
6.02%
The Vanguard Group, Inc.
5.03%
Private Capital Management
5.01%
Other
65.39%
Shareholders
Shareholders
Proportion
Opaleye Management Inc.
10.49%
Baum (Mark L)
8.06%
BlackRock Institutional Trust Company, N.A.
6.02%
The Vanguard Group, Inc.
5.03%
Private Capital Management
5.01%
Other
65.39%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.76%
Investment Advisor/Hedge Fund
19.70%
Individual Investor
16.06%
Hedge Fund
14.61%
Research Firm
2.10%
Pension Fund
0.83%
Bank and Trust
0.36%
Insurance Company
0.03%
Private Equity
0.02%
Other
25.53%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
368
21.63M
58.41%
-2.17M
2025Q3
360
21.75M
58.77%
-3.27M
2025Q2
345
26.63M
72.57%
-2.99M
2025Q1
354
25.78M
70.87%
-4.22M
2024Q4
350
26.13M
73.38%
-4.49M
2024Q3
325
25.90M
72.95%
-2.80M
2024Q2
296
24.70M
70.19%
-6.36M
2024Q1
284
26.34M
74.95%
-7.20M
2023Q4
279
28.26M
80.94%
-4.94M
2023Q3
275
28.51M
81.73%
-152.59K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Opaleye Management Inc.
3.90M
10.54%
--
--
Sep 30, 2025
Baum (Mark L)
2.99M
8.06%
+100.01K
+3.47%
Dec 12, 2025
BlackRock Institutional Trust Company, N.A.
2.23M
6.02%
-24.19K
-1.07%
Sep 30, 2025
The Vanguard Group, Inc.
1.86M
5.03%
+131.00
+0.01%
Sep 30, 2025
Private Capital Management
1.86M
5.01%
-89.70K
-4.61%
Sep 30, 2025
Kaufman (Daniel)
1.68M
4.55%
-222.91K
-11.69%
Aug 12, 2024
Boll (Andrew R)
811.18K
2.19%
+33.34K
+4.29%
Dec 12, 2025
State Street Investment Management (US)
794.28K
2.14%
+21.18K
+2.74%
Sep 30, 2025
Geode Capital Management, L.L.C.
775.64K
2.09%
-35.16K
-4.34%
Sep 30, 2025
Royce Investment Partners
533.01K
1.44%
-20.68K
-3.73%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
2.08%
Invesco Dorsey Wright Healthcare Momentum ETF
0.68%
First Trust Small Cap Growth AlphaDEX Fund
0.63%
iShares U.S. Pharmaceuticals ETF
0.46%
Invesco Dorsey Wright SmallCap Momentum ETF
0.37%
iShares Micro-Cap ETF
0.23%
First Trust Small Cap Core Alphadex Fund
0.2%
First Trust Multicap Growth Alphadex Fund
0.1%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.08%
Avantis US Small Cap Equity ETF
0.08%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.08%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.68%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.63%
iShares U.S. Pharmaceuticals ETF
Proportion0.46%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.37%
iShares Micro-Cap ETF
Proportion0.23%
First Trust Small Cap Core Alphadex Fund
Proportion0.2%
First Trust Multicap Growth Alphadex Fund
Proportion0.1%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.08%
Avantis US Small Cap Equity ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Harrow Inc?
The top five shareholders of Harrow Inc are:
Opaleye Management Inc. holds 3.90M shares, accounting for 10.54% of the total shares.
Baum (Mark L) holds 2.99M shares, accounting for 8.06% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.23M shares, accounting for 6.02% of the total shares.
The Vanguard Group, Inc. holds 1.86M shares, accounting for 5.03% of the total shares.
Private Capital Management holds 1.86M shares, accounting for 5.01% of the total shares.
Opaleye Management Inc. holds 3.90M shares, accounting for 10.54% of the total shares.
Baum (Mark L) holds 2.99M shares, accounting for 8.06% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.23M shares, accounting for 6.02% of the total shares.
The Vanguard Group, Inc. holds 1.86M shares, accounting for 5.03% of the total shares.
Private Capital Management holds 1.86M shares, accounting for 5.01% of the total shares.
What are the top three shareholder types of Harrow Inc?
The top three shareholder types of Harrow Inc are:
Opaleye Management Inc.
Baum (Mark L)
BlackRock Institutional Trust Company, N.A.
Opaleye Management Inc.
Baum (Mark L)
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Harrow Inc (HROW)?
As of 2025Q4, 368 institutions hold shares of Harrow Inc, with a combined market value of approximately 21.63M, accounting for 58.41% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.36%.
What is the biggest source of revenue for Harrow Inc?
In FY2025Q3, the Product Sales Net business generated the highest revenue for Harrow Inc, amounting to 71.50M and accounting for --% of total revenue.
